Serum Vascular Endothelial Growth Factor and Vascular Eduothelial Growth Factor Receptor-1 Levels in Patients With Fibromyalgia Syndrome

Basit Öğe Kaydı
dc.contributor.authorKaradag, Ahmet
dc.contributor.authorHayta, Emrullah
dc.contributor.authorCelik, Veysel Kenan
dc.contributor.authorBakir, Sevtap
dc.date.accessioned2024-10-26T18:00:06Z
dc.date.available2024-10-26T18:00:06Z
dc.date.issued2019
dc.departmentSivas Cumhuriyet Üniversitesi
dc.description.abstractObjectives: This study aims to compare the serum vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor-1 (VEGFR-1) levels between patients with fibromyalgia syndrome (FMS) and healthy controls. Patients and methods: The study included 40 female patients (mean age 39.9 +/- 10.2 years; range, 22 to 52 years) diagnosed with primary FMS according to the American College of Rheumatology criteria (1990) and 40 healthy female volunteers (mean age 40.9 +/- 8.3 years; range, 25 to 53 years). The sociodemographic data of both groups were recorded. The disease duration and the number of tender points were recorded for patients with FMS, and venous blood samples were collected from the two groups for the measurement of serum VEGF and VEGFR-1 levels. Results: The FMS and control groups were comparable in terms of age and body mass index (p>0.05). A comparison of the serum VEGF levels of the FMS and control groups revealed a statistically insignificant difference (p>0.05), while a comparison of the serum VEGF-1 levels of the FMS and control groups revealed a statistically significant difference (p<0.05). Conclusion: Serum VEGFR-1 levels were higher in patients with FMS, while the serum VEGF levels of the FMS patients did not differ from those of the healthy controls.
dc.identifier.doi10.5606/ArchRheumatol.2019.7265
dc.identifier.endpage418
dc.identifier.issn2148-5046
dc.identifier.issn1309-0283
dc.identifier.issue4
dc.identifier.pmid32010890
dc.identifier.scopus2-s2.0-85077334101
dc.identifier.scopusqualityQ4
dc.identifier.startpage414
dc.identifier.trdizinid359516
dc.identifier.urihttps://doi.org/10.5606/ArchRheumatol.2019.7265
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/359516
dc.identifier.urihttps://hdl.handle.net/20.500.12418/27525
dc.identifier.volume34
dc.identifier.wosWOS:000504829300007
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTurkish League Against Rheumatism
dc.relation.ispartofArchives of Rheumatology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectFibromyalgia syndrome
dc.subjectvascular endothelial growth factor
dc.subjectvascular endothelial growth factor receptor-1
dc.titleSerum Vascular Endothelial Growth Factor and Vascular Eduothelial Growth Factor Receptor-1 Levels in Patients With Fibromyalgia Syndrome
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu